替考拉宁

替考拉宁用途

本品可用于治疗各种严重的革兰阳性菌感染，包括不能用青霉素类和头孢菌素类其他抗生素者。本品可用于不能用青霉素类及头孢菌素类抗生素治疗或用上述抗生素治疗失败的严生葡萄球菌感染，或对其他抗生素耐药的葡萄球菌感染。已证明替考拉宁对下列感染有效：皮肤和软组织感染，泌尿道感染，呼吸道感染，骨髓炎，骨和关节感染，败血症，心内膜炎，持续不卧床腹膜透析相关性腹膜炎。在矫形手术具有革兰阳性菌感染的高危因素时，本品也可作预防用。
本品为与万古霉素类似的新糖肽抗生素，其抗菌谱及抗菌活性与万古霉素相似。对金葡菌的作用比万古霉素更强，不良反应更少。本品对革兰阳性菌如葡萄球菌、链球菌、肠球菌和大多厌氧性阳性菌敏感。临床主要用于金葡菌及链球菌属等敏感菌所致的严重感染，如心内膜炎、骨髓炎、败血症及呼吸道、泌尿道、皮肤、软组织等的感染。

替考拉宁名称

[ CAS 号 ]:
61036-62-2

[ 中文名 ]:
替考拉宁

[ 英文名 ]:
Teicoplanin

[英文别名 ]:

teichomycin
TEICOPLANIN
TEICOPLANIN,JP
Tagocid
TeicoplaninSodium
8327a
TEIC
Teicoplanin(sterile,non-sterile)
antibiotic8327a
Teocoplanin

替考拉宁生物活性

[ 描述 ]:

Teicoplanin是一种半合成的糖肽抗生素, 预防和治疗革兰氏阳性菌引起的严重感染, 包括耐Methicillin的金黄色葡萄球菌和肠球菌。

[ 相关类别 ]:

信号通路 >> 抗感染 >> 细菌

研究领域 >> 感染

[相关活性小分子]

替考拉宁物理化学性质

[ 密度 ]:
1.7±0.1 g/cm3

[ 分子式 ]:
C₁₃₀H₁₇₅Cl₂N₉O₃₇R₆

[ 分子量 ]:
2526.73

[ PSA ]:
662.41000

[ LogP ]:
0.40

[ 折射率 ]:
1.754

[ 储存条件 ]:
2-8℃

替考拉宁毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: WY1559000

CHEMICAL NAME :: Teicoplanin

CAS REGISTRY NUMBER :: 61036-62-2

LAST UPDATED :: 198910

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 14 mg/kg/31D-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Ear) - change in acuity

REFERENCE :: LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,613,1986

替考拉宁安全信息

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危害码 (欧洲) ]:
Xi

[ 危险品运输编码 ]:
NONH for all modes of transport

[ RTECS号 ]:
WY1559000

替考拉宁文献

Role of extra-cellular fatty acids in vancomycin induced biofilm formation by vancomycin resistant Staphylococcus aureus.

Pak. J. Pharm. Sci. 26(2) , 383-9, (2013)

In the present study a vancomycin resistant Staphylococcus aureus (S. aureus) (VRSA) (Labeled as CP2) was isolated from the blood of a post-operative cardiac patient is described. It harbors a plasmid...

A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.

Sci. Transl. Med. 7 , 290ra89, (2015)

Currently, no approved therapeutics exist to treat or prevent infections induced by Ebola viruses, and recent events have demonstrated an urgent need for rapid discovery of new treatments. Repurposing...

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

N. Engl. J. Med. 370(23) , 2169-79, (2014)

Dalbavancin, a lipoglycopeptide antibiotic agent that is active against gram-positive pathogens, has a long plasma half-life, allowing for once-weekly dosing. DISCOVER 1 and DISCOVER 2 were identicall...

更多文献